

**SENTARA HEALTH PLANS, INC.
CLINICAL CARE SERVICES**

Medical Policy: **Medical 34 F**

Subject: **Genetic Testing (Medicare) and Biomarkers**

See medical policy **34A Genetic Testing-Cancer Prevention, Diagnosis and Treatment**

See medical policy **34B for Genetic Testing—Pre-Treatment or Post Intervention**

See medical policy **34C for Genetic Testing—Cardiovascular and Developmental Diagnosis**

See medical policy **34D for Genetic Testing--- Preconceptional/Prenatal/Preimplantation Genetic Testing**

See Medical policy **34E-- Genetic Testing--Pharmacogenetic Testing**

Effective Date: January 01, 2014

Review Date: September 2013, 10/13; 11/13, 12/15, 2/21

Revised Date: October 2014; 11/14, 02/15, 7/19, 8/19, 10/19, 2/20, 5/20, 6/21, 7/21

Covered: **Medicare only.
See appropriate benefit document for specific coverage**

Exceptions: **Providers who are NOT contracted network Providers.**

Authorization: **Policy remains on Preauthorization without medical criteria but authorization for place of service at contracted network providers.**

Procedure:

Genetic testing (also called DNA-based tests) is among the newest and most sophisticated of techniques used to test for genetic disorders which involve direct examination of the DNA molecule itself.

Clinical Indications for all Medicare Members:

All Genetic testing services are covered with Contracted Network Providers.

For Reference only (Optima currently approves without medical criteria)

MEDICARE CLINICAL INDICATIONS GRID

Clinical Indications--For LCD coverage (Medicare Language):
<http://www.palmettogba.com/palmetto/palmetto.nsf/DocsCat/Home>

Indicator	Description
Y	Payable Medicare service
SE	Not covered - statutorily excluded from Medicare benefit
N	Not covered –failed reasonable/necessary Medicare criteria
L	Limited coverage per published LCD

CPT codes	CPT Descriptor	Covered
0047U	Oncotype DX for Prostate	Y
0005U	ExoDX Prostate (EPI, ExosomeDx Prostate, IntelliScore)	Y
81161	DMD Dup/Delet Analysis DMD	SE
81200	ASPA gene	SE
81201	APC(adaenomatous polyposis coli full gene sequence	SE
81202	known familial variants	SE
81203	duplication/deletion	SE
81205	BCKDHB gene	SE
81206	BCR/ABL1 gene major bp	Y

81207	BCR/ABL1 gene minor bp		Y
81208	BCR/ABL1 gene other bp		Y
81209	BLM gene		SE
81210	BRAF gene		Y
81211	BRCA1 & 2 seq and com dup/del		Y
81212	BRCA1 & 2 185&58385&6174 var		Y
81213	BRCA1 & 2 uncom dup/del var		Y
81214	BRCA1 full seq & com dup/del		Y
81215	BRCA1 full gene known fam variant		Y
81216	BRCA2 gene full sequence		SE
81217	BRCA2 gene known fam variant		Y
81220	CFTR gene com variants		SE
81221	CFTR gene known fam variants		SE
81222	CFTR gene dup/delet variants		SE
81223	CFTR gene full sequence		SE
81224	CFTR gene intron poly t		SE
81225	Cyp2c19 gene com variants		Y
81226	Cyp2d6 gene com variants		Y
81227	Cyp2c9 gene com variants		N
81228	Cytogen micrarray copy nمبر		SE
81229	Cytogen m array copy no&snp		SE
81235	EGFR (epidermal growth receptor)(non-small cell lung) gene analysis, common variants (eg exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)		Y
81240	F2 gene		Y
81241	F5 gene		Y
81242	FANCC gene		SE
81243	FMR1 gene detection		SE
81244	FMR1 gene characterization		SE
81245	FLT3 gene		Y
81250	G6PC gene		SE
81251	GBA gene		SE
81252	GJB2 (gap junction protein, common variants)		SE
81253	known familial variants		SE

81254	GJB6 gap junction protein gene analysis, common variants	SE
81255	HEXA gene	Y
81256	HFE gene	Y
81257	HBA1/HBA2gene	SE
81260	IKBKAP gene	SE
81261	IGH gene rearrange amp meth	Y
81262	IGH gene rraange dir probe	Y
81263	IGH vari regional mutation	Y
81264	IGH rearrangebn clonal pop	Y
81265	Str markers specimen anal	Y
81266	Str markers and addl	SE
81267	Chimerism anal no cell selec	Y
81268	Chimerism anal w/cell selec	Y
81270	JAK2 gene	Y
81275	KRAS gene	Y
81280	Long qt synd gene full sequence (12 genes)	SE
81281	Long qt synd known fam var	SE
81282	Long qt syn gene dup/dlt var (12 genes)	SE
81290	MCOLN1 gene	SE
81291	MTHFR gene	Y
81292	MLH1 gene full seq	Y
81293	MLH1 gene known variants	Y
81294	MLH1 gene dup/delete variant	Y
81295	MSH2 gene full seq	Y
81296	MSH2, gene known variants	Y
81297	MSH2, gene dup/delete variants	Y
81298	MSH6 gene full seq	Y
81299	MSH6 gene known variants	Y
81300	MSH6 gene dup/delete variants	Y
81301	Microsatellite instability	Y
81302	MECP2 gene full seq(Rhetts)	SE
81303	MECP2gene known variant(Rhetts)	SE
81304	MECP2 gene dup/delete variants (Rhetts)	SE
81310	NPM1 gene	Y
81315	PML/RAR alpha com breakpoints	Y
81316	PML/RAR alpha com 1	Y

	breakpoint		
81317	PMS2 gene full seq analysis		Y
81318	PMS2 known familial variants		Y
81319	PMS2 gene dup/delete variants		Y
81321	PTEN gene analysis, full sequence		Y
81322	known familial variants		Y
81323	duplication/deletion		Y
81324	PMP22 gene analysis, duplication/deletion		SE
81325	full sequence analysis		SE
81326	known familial variants		SE
81330	SMPD1 gene common variants		SE
81331	SNRPN/UBE3A gene		SE
81332	SERPINA1 gene		Y
81340	TRB @gene rearrange amplify		Y
81341	TRB @gene rearrange dirporbe		Y
81342	TRG gene rearrangement anal		Y
81350	UGT1A1 gene		SE
81355	VKORC1 gene		N
81370	HLA I & II typing lr		Y
81371	HLA I & II type verify lr		Y
81372	HLA I typing complete lr		Y
81373	HLA I typing 1 locus lr		Y
81374	HLA I typing 1 antigen lr		Y
81375	HLA II typing ag equiv lr		Y
81376	HLA II typing 1 locus lr		Y
81377	HLA II type 1 ag equiv lr		Y
81378	HLA I & II typing hr		Y
81379	HLA I typing complete hr		Y
81380	HLA I typing 1 locus hr		Y
81381	HLA I typing 1 allele hr		Y
81382	HLA II typing 1 loc hr		Y
81383	HLA II typing 1 allele hr		Y
81400	Tier 2		
81400	ABCC8		SE
81400	ACADM		SE
81400	ACE		Y
81400	AGTR1		SE
81400	CCR5		SE
81400	CLRN1		SE

81400	DPYD	SE
81400	DYT1 (TOR1A)	SE
81400	F2	Y
81400	F5	Y
81400	F7	Y
81400	F13B	Y
81400	FGB	Y
81400	FGFR3	SE
81400	Human Platelet Antigen ANTIGEN 1(HPA-1)	Y
81400	Human Platelet Antigen ANTIGEN 2(HPA-2)	Y
81400	Human Platelet Antigen ANTIGEN 3(HPA-3)	Y
81400	Human Platelet Antigen ANTIGEN 4(HPA-4)	Y
81400	Human Platelet Antigen ANTIGEN 5(HPA-5)	Y
81400	Human Platelet Antigen ANTIGEN 6(HPA-6)	Y
81400	Human Platelet Antigen ANTIGEN 9(HPA-9)	Y
81400	Human Platelet Antigen ANTIGEN 15 (HPA-15)	Y
81400	IVD	SE
81400	SERPINE1	Y
81400	SHOC2-NOONAN-LIKE SYNDROME	SE
81400	SMN1	SE
81400	SRY	SE
81401	Tier 2	
81401	ABL1 (c-abl oncogene 1)	Y
81401	ACADM (acyl-CoA dehydrogenase)	SE
81401	ADRB2	SE
81401	APOB	SE
81401	APOE	SE
81401	AR (androgen receptor)	SE
81401	ATN1	SE
81401	CBFB/MYH11	SE
81401	CBS	SE

81401	CCND1/IGH	Y
81401	CFH/ARMS2	SE
81401	CYP3A4	SE
81401	CYP3A5	SE
81401	CYFB-MYH11	Y
81401	DMPK (dystrophia myotonica-protein kinase)	SE
81401	E2A/PBX1	Y
81401	EML4-ALK	Y
81401	ETV6-RUNX1	Y
81401	EWSR1/ERG	Y
81401	EWSR1/FLI1	Y
81401	EWSR1/WT1	Y
81401	F11coagulation factor XI	Y
81401	FGFR3	SE
81401	FIP1L1-PDGFR	Y
81401	FOXO1/PAX3	Y
81401	FOXO1/PAX7	Y
81401	FXN (frataxin)	SE
81401	GALT (galactose-1-phosphate uridylyltransferase)	SE
81401	H19	SE
81401	HBB (hemoglobin, beta)	SE
81401	HTT (huntingtin)	SE
81401	KCNQ10T1 (KCNQ1 overlapping transcript 1)	SE
81401	MEG3/DLK1	SE
81401	MLL/AFF	SE
81401	MLL/MLLT3	SE
81401	MT-ATP6	SE
81401	MT-ND4, MT-ND6	SE
81401	MT-ND5 mitochondrially encoded tRNA leucine 1 [UUA/G] mitochondrially encoded NADH dehydrogenase 5)	SE
81401	MT-RNR1 (mitochondrially encoded 12S RNA)	SE
81401	MT-TK (mitochondrially	SE

	encoded tRNA lysine)	
81401	MT-TL1	SE
81401	MT-TS1	SE
81401	MUTYH (mutY homolog [E.coli])	Y
81401	NPM/ALK	Y
81401	PAX8/PPARG	Y
81401	PRSS1 (protease, serine, 1 [trypsin 1])	SE
81401	PYGM	SE
81401	RUNX1/RUNX1T1	Y
81401	SEPT9 (Septin 9)	SE
81401	SMN1/SMN2 (survival of motor neuron 1, telomeric/survival of motor neuron 2, centromeric)	SE
81401	TPMT (thiopurine S-methyltransferase)	Y
81401	TYMS (thymidylate synthetase)	Y
81401	VWF (von Willebrand factor)	Y
81402		
81402	CYP21A2	SE
81402	Chromosome 18q-	SE
81402	ESR1/PGR	SE
81402	IGH_BCL2	Y
81402	KIT	Y
81402	MEFV (Mediterranean fever) (eg, familial Mediterranean fever),	SE
81402	MPL	SE
81402	TRD	SE
81402	Uniparental disomy (UPD)	SE
81403		
81403	ABL1 (c-abl oncogene 1	Y
81403	ANG (angiogenin, ribonuclease, RNase A family, 5)	SE
81403	CEBPA	Y

81403	CEL (carboxyl ester lipase)	SE
81403	DAZ/SRY	SE
81403	F8 (coagulation factor VIII)	Y
81403	FGFR3 (fibroblast growth factor receptor 3)	SE
81403	GJB1 (gap junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene sequence	SE
81403	HBB (hemoglobin, beta, beta-globin beta thalassemia)	SE
81403	HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog Costello syndrome)	SE
81403	IDH1	Y
81403	IDH2 (isocitrate dehydrogenase 2)	Y
81403	JAK2 (Janus kinase 2)	Y
81403	KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene)	SE
81403	MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR)	SE
81403	MT-RNR1 (mitochondrially encoded 12S RNA)	SE
81403	MT-TS1 (mitochondrially encoded tRNA serine 1)	SE
81403	SMN1 (survival of motor neuron 1, telomeric)	SE
81403	VHL (von Hippel-Lindau tumor suppressor)	Y
81403	VWF (von Willebrand factor)	Y
81404		
81404	ACADS (acyl-CoA dehydrogenase)	SE
81404	AQP2 (aquaporin 2 [collecting duct])	SE
81404	ARX (aristaless related homeobox)	SE
81404	BTD (biotinidase)	SE

81404	CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle	SE
muscular dystrophy type 1C), full gene sequence		
81404	CDKN2A (cyclin-dependent kinase inhibitor 2A	Y
81404	CLRN1 (clarin 1)	SE
81404	CPT2 (carnitine palmitoyltransferase)	SE
81404	CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1)	SE
81404	DMPK (dystrophia myotonica-protein kinase	SE
81404	EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth	SE
81404	FGFR2 (fibroblast growth factor receptor 2)	SE
81404	FGFR3 (fibroblast growth factor receptor 3)	SE
81404	FKRP (Fukutin related protein)	SE
81404	FOXP1 (forkhead box G1)	SE
81404	FSHMD1A (facioscapulohumeral muscular dystrophy 1A)	SE
81404	FXN (frataxin)	SE
81404	HBA1/HBA2 (alpha globin 1 and alpha globin 2)	SE
81404	HBB (hemoglobin, beta, beta-globin)	SE
81404	HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes)	SE
81404	HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog)	SE
81404	KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10)	SE
81404	KIT (C-kit) (v-kit Hardy-Zuckerman 4 feline sarcoma)	Y
81404	LITAF (lipopolysaccharide-induced TNF factor)	SE
81404	MEFV (Mediterranean fever)	SE
81404	MEN1 (multiple endocrine neoplasia I)	SE
81404	NRAS (neuroblastoma RAS viral	Y

	oncogene homolog)	
81404	PDGFRA (platelet-derived growth factor receptor alpha polypeptide)	Y
81404	PDX1 (pancreatic and duodenal homeobox)	SE
81404	PRNP (prion protein)	SE
81404	PRSS1 (protease, serine, 1 [trypsin 1])	Y
81404	RAF1 (v-raf-murine leukemia viral oncogene homolog 1)	SE
81404	RET (RET proto-oncogene)	SE
81404	SDHD (succinate dehydrogenase complex, subunit D, integral membrane protein)	SE
81404	SLC25A4 (solute carrier family 25 [mitochondrial carrier; adenine nucleotide translocation],	SE
81404	TP53 (tumor protein 53)	SE
81404	TTR (transthyretin)	SE
81404	TYR (tyrosinase [oculocutaneous albinism IA])	SE
81404	USH1G (Usher syndrome 1G [autosomal recessive])	SE
81404	VHL (von Hippel-Lindau tumor suppressor)	Y
81404	VWF (von Willebrand factor)	SE
81405		
81405	ABCD1 (ATP-binding cassette, sub-family D [ALD],	SE
81405	ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA)	SE
81405	ACTC1 (actin, alpha, cardiac muscle 1)	SE
81405	APTX (aprataxin)	SE
81405	AR (androgen receptor	SE
81405	CHRNA4 (cholinergic receptor, nicotinic, alpha 4)	SE
81405	CHRNA2 (cholinergic receptor, nicotinic, beta 2 [neuronal])	SE
81405	CYP21A2 (cytochrome P450,	SE

	family 21, subfamily A, polypeptide2)		
81405	DFNB59 (deafness, autosomal recessive 59)		SE
81405	DHCR7 (7-dehydrocholesterol reductase)		SE
81405	EYA1 (eyes absent homolog 1 [Drosophila])		SE
81405	F9 (coagulation factor IX)		SE
81405	FH (fumarate hydratase)		SE
81405	FKTN (fukutin) (eg, limb-girdle muscular dystrophy)		SE
81405	GFAP (glial fibrillary acidic protein)		SE
81405	GLA (galactosidase, alpha)		SE
81405	HBA1/HBA2 (alpha globin 1 and alpha globin 2)		SE
81405	HNF1A (HNF1 homeobox A)		SE
81405	HNF1B (HNF1 homeobox B)		SE
81405	KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)		SE
81405	LAMP2 (lysosomal-associated membrane protein 2)		SE
81405	MEN1 (multiple endocrine neoplasia I)		Y
81405	MPZ (myelin protein zero)		SE
81405	MYL2 (myosin, light chain 2, regulatory, cardiac, slow)		SE
81405	MYL3 (myosin, light chain 3, alkali, ventricular, skeletal, slow)		SE
81405	MYOT (myotilin)		SE
81405	NEFL (neurofilament, light polypeptide)		SE
81405	NF2 (neurofibromin 2 [merlin])		SE
81405	NSD1 (nuclear receptor binding SET domain protein 1)		SE
81405	OTC (ornithine carbamoyltransferase)		SE
81405	PDHB (pyruvate dehydrogenase [lipoamide] beta)		SE
81405	PSEN1 (presenilin 1)		SE
81405	RET (RET proto-oncogene) (eg, multiple endocrine neoplasia, type 2A and familial medullary thyroid		SE

	carcinoma)		
81405	SDHB (succinate dehydrogenase complex, subunit B, iron sulfur) (eg, hereditary paragangli)		SE
81405	SDHC (succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa)		SE
81405	SGCA (sarcoglycan, alpha [50kDa dystrophin-associated glycoprotein])		SE
81405	SGCB (sarcoglycan, beta [43kDa dystrophin-associated glycoprotein])		SE
81405	SGCD (sarcoglycan, delta [35kDa dystrophin-associated glycoprotein])		SE
81405	SGCG (sarcoglycan, gamma [35kDa dystrophin-associated glycoprotein])		SE
81405	SHOC2 (soc-2 suppressor of clear homolog)		SE
81405	SMN1 (survival of motor neuron 1, telomeric)		SE
81405	SPRED1 (sprouty-related, EVH1 domain containing 1)		SE
81405	TGFBR1 (transforming growth factor, beta receptor 1)		SE
81405	TGFBR2 (transforming growth factor, beta receptor 2)		SE
81405	THRB (thyroid hormone receptor, beta)		SE
81405	TNNI3 (troponin 1, type 3 [cardiac])		SE
81405	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome, tumor		SE
81405	TPM1 (tropomyosin 1 [alpha])		SE
81405	TSC1 (tuberous sclerosis 1		SE
81405	VWF (von Willebrand factor)		Y
81406			
81406	ACADVL (acyl-CoA dehydrogenase, very long chain) (eg		SE
81406	ACTN4 (actinin, alpha 4)		SE

81406	ANO5 (anoctamin 5)		SE
81406	APP (amyloid beta [A4] precursor protein)		SE
81406	ATP7B (ATPase, Cu ⁺⁺ transporting, beta polypeptide)		SE
81406	BRAF (v-raf murine sarcoma viral oncogene homolog B1)		SE
81406	CAPN3 (Calpain 3)		Y
81406	CBS (cystathionine-beta-synthase)		SE
81406	CDH1 (cadherin 1, type 1, E-cadherin [epithelial])		SE
81406	CDKL5 (cyclin-dependent kinase-like 5)		SE
81406	DLAT (dihydrolipoamide S-acetyltransferase)		SE
81406	DLD (dihydrolipoamide dehydrogenase)		SE
81406	EYA1 (eyes absent homolog 1 Drosophila)		SE
81406	F8 (coagulation factor VIII)		SE
81406	GAA (glucosidase, alpha; acid)		SE
81406	GALT (galactose-1-phosphate uridylyltransferase)		SE
81406	GCDH (glutaryl-CoA dehydrogenase)		SE
81406	GCK (glucokinase [hexokinase 4])		SE
81406	HADHA (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase [trifunctional protein] alpha subunit)		SE
81406	F (hexosaminidase A, alpha polypeptide)		SE
81406	HNF4A (hepatocyte nuclear factor 4, alpha)		SE
81406	IVD (isovaleryl-CoA dehydrogenase)		SE
81406	JAG1 (jagged 1) (SE
81406	LDB3 (LIM domain binding 3) (eg, familial)		SE
81406	LMNA (lamin A/C)		SE
81406	MAP2K1 (mitogen-activated protein kinase 1)		SE
81406	MAP2K2 (mitogen-activated		SE

	protein kinase 2)		
81406	MCCC2 (methylcrotonoyl-CoA carboxylase 2 [beta])		SE
81406	MUTYH (mutY homolog [E. coli])		SE
81406	NF2 (neurofibromin 2 [merlin])		SE
81406	NOTCH3 (notch 3)		SE
81406	NSD1 (nuclear receptor binding SET domain protein 1)		SE
81406	OPA1 (optic atrophy 1) (eg, optic atrophy),		SE
81406	PAH (phenylalanine hydroxylase)		SE
81406	PALB2 (partner and localizer of BRCA2)		SE
81406	PAX2 (paired box 2)		SE
81406	PC(pyruvate carboxylase)		SE
81406	PCCB (propionyl CoA carboxylase, beta polypeptide)		SE
81406	PDHA1 (pyruvate dehydrogenase [lipoamide] alpha1)		SE
81406	PDHX (pyruvate dehydrogenase complex, component)		SE
81406	POLG (polymerase [DNA directed], gamma)		SE
81406	POMGNT1 (protein O-linked mannose beta1, 2-N acetylglucosaminyltransferase)		SE
81406	POMT1 (protein-O-mannosyltransferase 1)		SE
81406	POMT2 (protein-O-mannosyltransferase 2)		SE
81406	PRKAG2 (protein kinase, AMP-activated, gamma 2 non-catalytic subunit)		SE
81406	PSEN2 (presenilin 2[Alzheimer's disease 4])		SE
81406	PTPN11 (protein tyrosine phosphatase, non-receptor type 11)		SE
81406	PYGM (phosphorylase, glycogen, muscle) (SE
81406	RAF1 (v-raf-1 murine leukemia viral oncogene homolog 1)		SE
81406	RET (ret-proto-oncogene)		Y
81406	RYR1 (ryanodine receptor 1,		SE

	skeletal)		
81406	SLC26A4 (solute carrier family 26, member 4)		SE
81406	SLC9A6 (solute carrier family 9 [sodium/hydrogen exchanger] member 6)		SE
81406	SOS1 (son of sevenless homolog 1)		SE
81406	TAZ (tafazzin)		SE
81406	TNNT2 (troponin T, type 2 [cardiac])		SE
81406	TSC1 (tuberous sclerosis 1)		SE
81406	TSC2 (tuberous sclerosis 2)		SE
81406	UBE3A (ubiquitin protein ligase)		SE
81406	VWF (von Willebrand factor)		SE
81407			
81407	ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8)		SE
81407	CHD7 (chromodomain helicase DNA binding protein 7)		SE
81407	F8 (coagulation factor VIII)		SE
81407	JAG1 (jagged 1)		SE
81407	MYBPC3 (myosin binding protein C, cardiac)		SE
81407	MYH6 (myosin, heavy chain 6, cardiac muscle, alpha)		SE
81407	MYH7 (myosin, heavy chain 7, cardiac muscle, beta)		SE
81407	MYO7A (myosin VIIA)		SE
81407	NOTCH1 (notch 1)		SE
81407	OPA1 (optic atrophy)		SE
81407	PCDH15 (protocadherinrelated 15)		SE
81407	SCN1A (sodium channel, voltage-gated, type 1, alpha subunit)		SE
81407	SCN5A (sodium channel, voltage-gated, type V, alpha subunit)		SE
81407	TSC2 (tuberous sclerosis 2)		SE
81407	USH1C (Usher syndrome 1C)		SE
81408			

81408	ATM (ataxia telangiectasia mutated)		SE
81408	CDH23 (cadherin-related 23)		SE
81408	COL1A1 (collagen, type I, alpha 1)		SE
81408	COL1A2 (collagen, type I, alpha 2)		SE
81408	DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive])		SE
81408	FBN1 (fibrillin 1)		SE
81408	NF1 (neurofibromin 1)		SE
81408	RYR1 (ryanodine receptor 1, skeletal)		SE
81408	USH2A (Usher syndrome 2A [autosomal recessive, mild])		SE
81408	VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3),		SE
81599	COLOGAURD		Covered as a preventive Service for members aged 50-84 every 3 years
81403	CTNNB1		N
81404	STK11		N
81404	FGFR1		N
81404	FGFR2		N
81404	FGFR3		N
81407	NOTCH1		N
81479	AKT1		N
81479	DDR2		N
81479	ERBB2		N
81479	ERBB4		N
81479	FBXW7		N
81479	PIK3CA		N
81479	ProMark		Y
81541	Prolaris		Y

81542	Decipher		Y
88368	MET amplifications		N
88368	ROS1		N

Descriptor column abbreviation key Abbreviation Key	lower case claim text
Amplified	amp
Additional	add
Breakpoints	bp
Common	c
common duplilcations_deletions	cdup_del
common variants	cv
comon breakpoints	cbp
Deletion	del
direct probe	dp
Duplication	dup
duplication_deletion	dup_del
Each	ea
extended targeted sequence analysis	etsa
full gene sequence	fgs
gene rearrangement	gr
high resolution	hr
insertion/deletion variant	idv
inversion analysis	ia
known familial variants	kfv
low resolution	lr
major breakpoint	majbp
major breakpoint region	mbpr
methylation analysis	ma
Microsatellite instability	MSI
minor breakpoint	minbp
minor cluster region	mcr
Number	nmbr
Qualitative	qual

Quantitative	quan
short tandem repeat	str
single breakpoint	sbp
somatic mutation	sm
tandem repeat variant	trv
targeted gene analysis	tga
targeted sequence analysis	tsa
translocation analysis	ta
Variant	var

The following tests have completed the MoIDX Program application review and/or technical assessment and meet Medicare reasonable and necessary criteria:

Test Name	CPT Code(s)
Afirma™	84999
Allomap	86849
Avise PG	84999
Cancer TYPE ID	84999
cobas® 4800 BRAF V600	84999
cobas EGFR	81479
Corus® CAD	84999
Decipher®	81542
ExoDX Prostate (EPI, ExosomeDx Prostate, IntelliScore)	0005U
EndPredict	81522
HERmark®	84999
MammaPrint™	81521
For Oncotype DX® Breast Approved if meets criteria established in 34A	81519
Oncotype DX	0045U

Breast Cancer Assay with DCIS recurrence score	
Oncotype DX® Colon	84999
Oncotype DX® for Prostate	0047U
Percepta Bronchial Genomic Classifier	81479
Progensa® PCA3	84999
Prolaris®	81541
ProMark®	81479
therascreen EGFR	81479
therascreen KRAS	81479
Tissue of Origin	84999
Vectra™ DA	84999
Vysis	88367(2)OR 88368(2)

REFERENCES

- Agency for Healthcare Research and Quality (AHRQ)
- Diagnostic and Therapeutic Technology Assessment (DATTA) Review
- Specialty Association Guidelines
- SHC Guidelines
- Government Regulations
- Literature Review
- Specialty Advisors
- Winifred S. Hayes, Inc.
- Uptodate
- NCD
- LCD

REFERENCES

(2021). Retrieved Jun 30, 2021, from CMS: <https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=ExoDx%20Prostate&keywordType=all&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance>

(2021). Retrieved Jun 30, 2021, from EncoderPro: https://www.encoderpro.com/epro/cptHandler.do?_k=101*0005U&_a=view&searchTerms=0005U&_mrad=true&#selected

Cancer Facts & Figures. (2021). Retrieved Jun 30, 2021, from American Cancer Society (ACS): <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf>

Clinical Laboratory Improvement Amendments (CLIA). (2020, Feb 25). Retrieved Jun 30, 2021, from FDA: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.4250>

ExoDx Prostate (IntelliScore; Exosome Diagnostics Inc.) - ARCHIVED Sep 18, 2020. (n.d.). Retrieved Jun 30, 2021, from Hayes: <https://evidence.hayesinc.com/report/gtsyn.exodx.4548>

ExoDx™ Prostate Test. (2021). Retrieved Jun 30, 2021, from Exosome Diagnostics: <http://www.exosomedx.com/physicians/exodx-prostate-test>

In Vitro Diagnostics. (2019). Retrieved Jun 30, 2021, from FDA: <https://www.fda.gov/medical-devices/products-and-medical-procedures/in-vitro-diagnostics>

Local Coverage Determination (LCD): MolDX: Molecular Diagnostic Tests (MDT) (L35025). (2019, Dec 12). Retrieved Jun 30, 2021, from CMS LCD: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=35025&ver=91&bc=CAAAAAAAAAAAAA>

Molecular prognostic tests for prostate cancer. (2021, Feb 24). Retrieved Jun 30, 2021, from UpToDate: https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer?search=Prostate%20biomarker&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021,

May 10). Retrieved Jun 30, 2021, from AIM Clinical Appropriateness Guidelines: <https://aimproviders.com/genetictesting/wp-content/uploads/sites/15/2021/01/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-5-10-2021.pdf>

PCA3 Detection Test For Prostate Cancer - ARCHIVED Jun 7, 2018. (n.d.). Retrieved Jun 30, 2021, from Hayes 2: <https://evidence.hayesinc.com/report/gte.pca1775>

Position Statement: Genomic testing in prostate cancer. (2018). Retrieved Jun 30, 2021, from American Association of Clinical Urologists (AACU): https://aacuweb.org/docs/position-statements/ps_genomic-testing-in-prostate-cancer.aspx

Proposed Local Coverage Determination (LCD): MoIDX: Biomarkers to Risk-Stratify Patients at Increased Risk for PROSTATE Cancer (DL38985). (2021). Retrieved Jun 30, 2021, from CMS LCD: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=38984&ver=7&keyword=ExoDx%20Prostate&keywordType=all&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAAA&KeyWordLookUp=D>

Prostate Cancer - PCA3 Gene (A-0855), 25th Edition. (2021). Retrieved Jun 30, 2021, from MCG: <https://careweb.careguidelines.com/ed25/index.html>

Prostate Cancer. (2021). Retrieved Jun 30, 2021, from European Association of Urology (EAU): <https://uroweb.org/guideline/prostate-cancer/#5>

Prostate Cancer. (2021, Feb 17). Retrieved Jun 30, 2021, from National Comprehensive Cancer Network - NCCN Guidelines: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Prostate Cancer Screening. (2021). Retrieved Jun 30, 2021, from Dynamed: <https://www.dynamed.com/prevention/prostate-cancer-screening>

Provider Manuals. (2021). Retrieved Jun 30, 2021, from DMAS: <https://www.viriniamedicaid.dmas.virginia.gov/wps/portal/transmittals>

(2020). Retrieved May 13, 2020, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search/search-results.aspx?SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=53&KeyWord=TSC2&KeyWordLookUp=Doc&KeyWo>

(2020, Jun 24). Retrieved Jun 03, 2021, from MCG:

<https://careweb.careguidelines.com/ed24/index.html>

(2021). Retrieved Jun 03, 2021, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/general-information/procedure-fee-files-cpt-codes/#searchCPT>

Decipher Prostate Biopsy (Decipher Biosciences). (2021, Apr 18). Retrieved Jun 03, 2021, from Hayes, Inc: <https://evidence.hayesinc.com/report/gte.decipher4623>

Decipher Prostate RP (Decipher Biosciences). (2021, Apr 18). Retrieved Jun 02, 2021, from Hayes: <https://evidence.hayesinc.com/report/gte.decipher3356>

Feng, F., & al, e. (2021, Apr 01). Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. Retrieved Jun 03, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/33570548/>

LCD: MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38292). (2020, Nov 08). Retrieved Jun 03, 2021, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=38292&ver=8&keyword=Decipher&keywordType=starts&areaId=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAA&KeyWordLookUp=Doc&Ke>

Management of Localized or Locally Advanced Prostate Cancer. (2021, Jan 04). Retrieved Jun 06, 2021, from DynaMed: https://www.dynamed.com/management/management-of-localized-or-locally-advanced-prostate-cancer#TOPIC_XJ3_DYQ_2NB

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. (2019, Dec 12). Retrieved Jun 03, 2021, from American Society of Clinical Oncology: <https://ascopubs.org/doi/full/10.1200/JCO.19.02768>

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2021, Sep 06). Retrieved Jun 03, 2021, from AIM Specialty Health: <https://aimproviders.com/geneticstesting/wp-content/uploads/sites/15/2021/03/GT04-Molecular-Testing-of-Solid-and-Hematologic-Tumors-9-6-2021.pdf>

Prostate Cancer with Evidence Blocks. (2021, Mar 19). Retrieved Jun 03, 2021, from National Comprehensive Cancer Network: https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf

Ross, A., D'Amico, A., & Freedland, S. (2021, Feb 24). Molecular prognostic

tests for prostate cancer. Retrieved Jun 03, 2021, from UpToDate:
https://www.uptodate.com/contents/molecular-prognostic-tests-for-prostate-cancer?search=Decipher%20prostate&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H40176779

(2020). Retrieved May 14, 2020, from Department of Medical Assistance Services:
<https://www.viriniamedicaid.dmas.virginia.gov/wps/portal/ProviderManual>

Clinical Appropriateness Guidelines for Genetic Testing. (2020). Retrieved May 13, 2020, from AIM Specialty Health:
<https://aimspecialtyhealth.com/resources/clinical-guidelines/genetic-testing/>

Gu, X., Han, L., Chen, J., Wang, J., Hao, X., Zhang, Y., . . . He, Y. (2018, Apr). Antenatal screening and diagnosis of tuberous sclerosis complex by fetal echocardiography and targeted genomic sequencing. Retrieved May 14, 2020, from PubMed: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908597/>

Milunsky, A., Ito, M. M., Flynn, M., & Milunsky, J. (2009, Mar). Prenatal molecular diagnosis of tuberous sclerosis complex. Retrieved May 14, 2020, from PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/19254590>

Neuroendocrine and Adrenal Tumors. (2019, Mar 06). Retrieved May 13, 2020, from National Comprehensive Cancer Network:
<https://cse.google.com/cse?cx=007894372670309631110:vocdaeamxuy&ie=UTF-8&q=Cochlear%20implants&safe=high>

Northrup, H. K. (2013). Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Retrieved May 14, 2020, from Pediatric Neurology:
<https://www.pedneur.com/article/S0887-8994%2813%2900490-6/pdf>

Randle, S. (2019, Jul 11). Tuberous sclerosis complex: Genetics, clinical features, and diagnosis. Retrieved May 13, 2020, from UpToDate:
https://www.uptodate.com/contents/tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis?search=tuberous%20sclerosis&source=search_result&selectedTitle=1~105&usage_type=default&display_rank=1#H140866458

Tuberous Sclerosis Complex. (2020, Feb 07). Retrieved May 14, 2020, from DynaMed: https://www.dynamed.com/condition/tuberous-sclerosis-complex#GENETIC_TESTING

(2020). Retrieved February 14, 2020, from U.S. Food and Drug Administration:
<https://search.usa.gov/search?>

(2020). Retrieved February 14, 2020, from Optum360 EncoderPro:
<https://www.encoderpro.com/epr/cptHandler.do?>

(2020). Retrieved February 14, 2020, from Department of Medical Assistance Services (DMAS): <http://www.dmas.virginia.gov/#/searchcptcodes>

Assay and Predictive Markers Guidelines. (2015, July 20). Retrieved February 14, 2020, from The American Society of Clinical Oncology (ASCO):
<https://www.asco.org/research-guidelines/quality-guidelines/guidelines/assays-and-predictive-markers#/9676>

Chemotherapy for Early and Locally Advanced Breast Cancer. (2018, November 30). Retrieved February 14, 2020, from DynaMed:
<https://www.dynamed.com/management/chemotherapy-for-early-and-locally-advanced-breast-cancer#GUID-91CDF50C-5506-4EF1-A4F5-F9D2F053A0B0>
EndoPredict (Myriad Genetics). (2019, June 12). Retrieved February 14, 2020, from Hayes: <https://evidence.hayesinc.com/report/gte.endopredict3972>

EndoPredict. (2019). Retrieved February 14, 2020, from Myriad Genetics, Inc.:
<https://endopredict.com/>

EndoPredict Test. (2019, November 6). Retrieved February 14, 2020, from Breastcancer.org:
<https://www.breastcancer.org/symptoms/testing/types/endopredict-test>

Evidence Summary: Screening for Breast Cancer. (2016, August). Retrieved February 14, 2020, from U.S. Preventive Services Task Force:
<https://www.uspreventiveservicestaskforce.org/Page/Document/evidence-summary-screening-for-breast-cancer/breast-cancer-screening1>

Invasive Breast Cancer: NCCN Guidelines for patients. (2018). Retrieved February 14, 2020, from NCCN:
<https://www.nccn.org/patients/guidelines/content/PDF/breast-invasive-patient.pdf>

LCD MoIDX: EndoPredict Breast Cancer Gene Expression Test (L37264) Revision 6 LCD: L37264R006 (MCR), 23rd Edition. (2020). Retrieved February 13, 2020, from MCG: <https://careweb.careguidelines.com/ed23/index.html>

Local Coverage Article: Billing and Coding: MoIDX: ENDOPREDICT Breast Cancer Gene Expression Test (A56963). (2020, January 1). Retrieved February 14, 2020, from CMS: <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=56963&ver=7&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=53&Keyword=Endo>

Local Coverage Determination (LCD): MoIDX: EndoPredict Breast Cancer Gene Expression Test (L37264). (2019, November 7). Retrieved February 13, 2020, from CMS1: <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37264&ver=17&Date=&DocID=L37264&bc=iAAAABAAAAA&>

Medicare Benefit Policy Manual Chapter 15 – Covered Medical and Other Health Services 80.1 - Clinical Laboratory Services. (2020). Retrieved February 14, 2020, from CMS2: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>

Molecular Testing of Solid and Hematologic Tumors and Malignancies. (2019, December 9). Retrieved February 14, 2020, from AIM Specialty Health: https://aimproviders.com/genetictesting/wp-content/uploads/sites/15/2019/11/MolecularTestingofSolidandHematologicTumor sandMalignancies_Dec_2019.pdf

Myriad EndoPredict® Technical Specifications. (2019, December 10). Retrieved February 4, 2020, from Myriad Genetics: <https://myriad-library.s3.amazonaws.com/technical-specifications/EndoPredict-Technical-Specifications.pdf>

NCD Next Generation Sequencing (NGS) (90.2) Version 1 NCD: N902v1 (MCR), 23rd. (2018, March 16). Retrieved February 14, 2020, from MCG Health: <https://careweb.careguidelines.com/ed23/index.html>

Prognostic and predictive factors in early, non-metastatic breast cancer. (2020, January 16). Retrieved February 14, 2020, from UpToDate: https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-early-non-metastatic-breast-cancer?search=Endopredict&source=search_result&selectedTitle=1~4&usage_type=default&display_rank=1

Carrier Screening for Genetic Conditions, Number 691. (2017, March). Retrieved October 8, 2019, from American College of Obstetricians and Gynecologists: <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Genetics/Carrier-Screening-for-Genetic-Conditions>

Clinical Appropriateness Guidelines: Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis. (2019, September 9). Retrieved Oct 8, 2019, from AIM Specialty Health: https://aimspecialtyhealth.com/wp-content/uploads/2019/07/ReproductiveCarrierScreeningandPrenatalDiagnosis_Sep_2019.pdf

HEXA Gene Analysis Coding and Billing Guidelines. (2019, Jan 01). Retrieved

Oct 8, 2019, from Centers for Medicare and Medicaid Services:
<https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=53598&ver=14&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=53&Keyword=HEX>

HGNC Data for HEXA. (2019). Retrieved October 8, 2019, from HUGO Gene Nomenclature Committee: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4878

Late-onset Tay–Sachs disease, Volume 17, Issue 5. (2017, October 17).
doi:10.1136/practneurol-2017-001665

NCCN Guidelines. (2019). Retrieved Oct 8, 2019, from National Comprehensive Cancer Network: https://www.nccn.org/professionals/physician_gls/default.aspx

Preconception and Prenatal Carrier Screening for Genetic Disease More Common in the Ashkenazi Jewish Population and Others With A Family History Of These Disorders. (2019, Aug 1). Retrieved Oct 8, 2019, from UpToDate: https://www.uptodate.com/contents/preconception-and-prenatal-carrier-screening-for-genetic-disease-more-common-in-the-ashkenazi-jewish-population-and-others-with-a-family-history-of-these-disorders?search=tay%20sachs&source=search_result&selectedTitle=1~2

Prenatal Diagnosis of Tay-Sachs Disease, MIMB, volume 1885. (2018, December 1). doi:10.1007/978-1-4939-8889-1_16

Tay - Sachs Disease (TSD) Testing in Individuals of Non–Ashkenazi Jewish Origin. (2014, December 12). Retrieved Oct 8, 2019, from Hayes, Inc.: <https://evidence.hayesinc.com/report/gte.taysachs2351>

Tay-Sachs Disease. (2018, November 30). Retrieved Oct 8, 2019, from DynaMed Plus: <https://www.dynamed.com/condition/tay-sachs-disease#GUID-403E22E0-1B95-4631-A687-EFD512585AFD>

Tay - Sachs disease and Variants - HEXA Gene, ACG: A-0614 (AC). (2019, Feb 11). Retrieved Oct 8, 2019, from MCG: <https://careweb.careguidelines.com/ed23/index.html>

LCD--Palmetto GBA--
<http://www.palmettogba.com/palmetto/palmetto.nsf/DocsCat/Home>